The root of Polygala tenuifolia WILLD (PT) (Japanese name: Onji) is a well-known traditional Chinese medicine used as an expectorant, a tonic, a tranquillizer and an anti-dementia drug. However, basic researches of the anti-dementia effects are very few in spite of PT being generally recognized as a good herbal drug for amnesia. It was reported that 80% ethanol extract of PT and the methanol extract of PT reverse scopolamine-induced cognitive impairments in rats. 1, 2) Acetylcholinestrase (AChE) activity is inhibited in vitro by 80% ethanol extract of PT.
Acetylcholinestrase (AChE) activity is inhibited in vitro by 80% ethanol extract of PT. 1, 3) Onjisaponin F, a constituent in PT, increases cholineacetyltransferase (ChAT) mRNA level in rat basal forebrain cell, and. Taken together, transient enhancement of cholinergic systems by PT may be involved in the memory improvement seen in like the scopolamine model. However, practical dementia is caused by irreversible neuronal damage involving neuronal death, neuritic atrophy and synaptic loss. Especially in case of Alzheimer's disease, neuritic atrophy and synapse loss are earlier events than neuronal death are, and are critical for memory disorder. [4] [5] [6] [7] [8] Previous our studies suggested that compounds which showed synaptic regeneration activity in cultured neurons were also active for memory impairment in vivo using Alzheimer's disease model mice. [9] [10] [11] Although protective effects of PT on neuronal death were shown in amyloid b (Ab), glutamate or NMDA-induced neuronal damage, effects of PT on atrophy of neuritis and synaptic loss never have been investigated yet. 1, 12) Therefore, we aimed in this study to characterize activities of PT under Ab-induced neuritic damage.
MATERIALS AND METHODS

Materials
Thirty gram of roots of Polygala tenuifolia WILLD (PT) was extracted with 600 ml of water at 100°C for 40 min. This crude drug was purchased from Tochimoto Tenkaido (Osaka, Japan). The decoction was evaporated under reduced pressure and freeze-dried of extract powder (yield: 8.02 g). The extract was then dissolved in sterilized distilled water at 1000 times concentrations of final concentrations. Ab (25-35) (Sigma, Saint Louis, MO, U.S.A.) was dissolved in sterile distilled water at a concentration of 5 mM, and was incubated at 37°C for 3 d to allow fibril formation. [Gly 14 ]-Humanin was purchased from Phoenix Pharmaceuticals (Belmont, CA, U.S.A.) as a positive control for neuronal protection. A monoclonal antibody to phosphorylated neurofilament-H (NF-H) was purchased from Sternberger Monoclonals (Lutherville, MD, U.S.A.). A monoclonal antibody to microtubule-associated protein 2 (MAP2), an antiserum to MAP2, polyclonal antibody to MAP2 and a monoclonal antibody to synaptophysin were purchased from Chemicon (Temecula, CA, U.S.A.). Alexa Fluor 488-conjugated goat anti-mouse IgG and Alexa Fluor 546-conjugated goat antirabbit IgG were purchased from Molecular Probes (Eugene, OR, U.S.A.). Aqua Poly Mont was purchased from Polyscience (Warrington, PA, U.S.A.).
Primary Culture Embryos were removed from pregnant Sprague Dawley rats (Japan SLC, Shizuoka, Japan) at 17 or 19 d of gestation. The animals were handled in accordance with the Guideline for the Care and Use of Laboratory Animals of University of Toyama.
The cortices were dissected, and the dura mater was removed. The cells minced and dissociated were plated on 8-well chamber slides or 12-well plate (Falcon, Franklin Lakes, NJ, U.S.A.) coated with poly-D-lysine (5 mg/ml) at 37°C in a humidified incubation with 10% CO 2 with Neurobasal media including 12% horse serum. The density of the cells was 1.0ϫ10 5 cells/ml for short term culture, or 1.5ϫ10 5 cells/ml for long term culture.
Drug Treatment The cells were cultured in medium containing serum for short-term culture or in medium containing 2% B-27 supplement without serum for long-term culture. In case of short-term culture, the cells were cultured for 3 d and were treated with 10 mM Ab Analysis of Neurite Outgrowth Rat cortinal neurons on 8-well chamber slides were fixed by 4% paraformaldehyde and immunostained with a monoclonal antibody to phosphorylated neurofilament-H (NF-H) (dilution 1 : 1000) as an axonal marker or a monoclonal antibody to MAP2 (dilution 1 : 1000) as a dendrite marker. Alexa Fluor 488-conjugated goat anti-mouse IgG dilution (1 : 200) was used as secondary antibodies. The slides were mounted with Aqua Poly Mont. Fluorescence images (four images per treatment) were captured by a fluorescence microscope (AX-80, Olympus, Tokyo, Japan) at 425 mmϫ320 mm. The length of neurites positive for phosphorylated NF-H or MAP2 was measured using an image analysis software Neurocyte (Kurabo, Osaka, Japan).
Analysis of Synaptic Formation After the drug treatment, the cells were fixed and double-immunostained with a combination of monoclonal antibody to synaptophysin (dilution 1 : 500) as a presynaptic marker and a polyclonal antibody to MAP2 (dilution 1 : 1000) as a dendrite marker. Alexa Fluor 488-conjugated goat anti-mouse IgG (1 : 200) and Alexa Fluor 568-conjugated goat anti-rabbit IgG (1 : 200) were used as secondary antibodies. The slides were mounted with Aqua Poly Mont. The fluorescence images were captured by a confocal laser scanning microscope (Radiance 2100, Bio Rad, Hercules, CA, U.S.A.) at 302 mmϫ302 mm, and four images were captured per treatment. The area of positive puncta to synaptophysin on each dendrite was measured using an image analyzer ATTO densitograph (ATTO, Tokyo, Japan). The length of the dendrites was measured using Image J software (http://rsb.info.nih.gov/ij/index. html) .
Cell Viability Assessment Cell viability was determined by calcein staining. Cells on 8-well chamber slides were rinsed by phosphate-buffer saline (PBS), and were incubated with 6 mM calcein AM (Dojindo, Kumamoto, Japan) for 40 min at 37°C. After rinsing by PBS, cells were fixed by 4% paraformaldehyde and mounted. Fluorescence images and bright field images were simultaneously captured (four images per treatment) by AX-80 microscope. The percentage of dead cell was valued as the ratio of dead cells (calceinnegative) to total cells. The total cell number was counted in bright-field photos.
Statical Analysis Statistical comparisons were performed by the Student's t-test, or one-way analysis of variance followed by Bonferroni's method. Values of pϽ0.05 were considered significant. The means of the data presented together with S.E.M.
RESULTS
Extract of P. tenuifolia Activates Extension of Axons, But Not Dendrites, after Ab b (25-35)-Induced Damage
Rat cortical neurons were cultured with Ab (25-35) for 4 d, then PT extract (0.1, 1, 10, 100 mg/ml) or vehicle (water) was added. After drug treatment for 5 d, cells were fixed and immunostained for phosphorylated NF-H or MAP2. Both axons (Fig. 1) and dendrites (Fig. 2) were significantly shortened after treatment with Ab (25-35). Treatment with PT extract resulted in a significant increase in axon in a dose-dependently manner (Fig. 1) . One way ANOVA revealed a significant dose-dependent effect in the extract-treated group (pϭ0.00000747). The length of axons reached to the same level of control by treatment with 1 mg/ml PT extract. Higher doses were more effective. In contrast, Ab (25-35)-induced atrophy of dendrites was not recovered by treatments with PT extract at any doses (Fig. 2) . (Fig. 3) . Treatment with PT extract did not increased synaptoshysin-positive areas (7.2Ϯ0.17 mm 2 /mm dendrite), indicating that PT extract had no synaptogenesis activity. NGF treatment also did not increase synaptophysinpositive areas (6.67Ϯ0.42 mm 2 /mm dendrite), which is consistent with previous results. 
Extract of P. tenuifolia Had No Effect on Reconstructing Synapses in Damaged Neurons
Rat cortical neurons were cultured for 21 d to construct mature synapses, and then Ab (25-35) was added to the cells to induce synaptic loss. Four days later, PT extract (100 mg/ml), nerve growth factor (NGF; 100 ng/ml), or vehicle (water) was added to the cells. Seven days later, the cells were fixed and double-immunostained for synaptophysin and MAP2. Synaptophysin-positive areas in vehicle-treated neurons at 11 d after treatment with Ab (25-35) (7.6Ϯ0.22 mm 2 /mm dendrite) were significant reduced compared with control (11.8Ϯ0.23mm 2 /mm dendrite)
DISCUSSION
In the brain of Alzheimer's disease, it is well known that cholinergic neurons are selectively lost. 15) Based on the fact, cholinesterase inhibitors such as donepezil were developed as anti-Alzheimer's disease drugs, and are clinically used at the present. However, these cholinesterase inhibitors play a role just slowing the progress of disease, but not curing it. 16, 17) It may be due to that supplying acetylcholine is not expected when neuritic atrophy, synaptic loss and neuronal death are progressed severely. Although PT was classically mentioned as anti-dementia drug, basic research showed only enhancement of the cholinergic function in vitro or scopolamine-induced temporal memory deficit. 1, 2, 12) This study showed for the first time effects of PT extract on neuronal morphological plasticity and cell damage under Ab (25-35)-induced neurodegenerative condition using rat cortical neurons. In Alzheimer's disease, neuritic atrophy and synaptic loss occur prior to neuronal death event, and may be the first trigger of the memory impairment. 8) Present data clearly indicated PT extract enhances axonal regeneration, but not dendritic extension and synaptic formation under Ab (25-35)-induced atrophy. Although extension of axons and dendrites must be essential for recovery from synaptic loss, our data suggests that at least axonal extension does not necessary lead to synaptic formation.
PT extract strongly inhibited Ab (25-35)-induced cell damage. The inhibitory effect of PT extract was shown when added 4 d after the treatment with Ab (25-35) (Fig. 4) . In Fig. 4B , cell viability was evaluated in attached cells, and was recovered to the same level of control by 10 mg/ml PT extract in spite of post treatment, suggesting that the cell damage is reversible, and the 10 mg/ml PT extract may have stronger effect on repair the cell damage than 100 mg/ml PT extract. [Gly 14 ]-Humanin peptide also had repair effect on Ab (25-35)-induced cell damage. Somehow, 10 mg/ml PT extract was more effective than 100 mg/ml extract in neuronal protection. In contrast, axonal extension was the most effective by treatment with 100 mg/ml PT extract. In addition, dendritic atrophy and synaptic loss were not improved by any doses of PT extract. These results suggest that the axonal -35) , the cells were treated with PT extract (10, 100 mg/ml), [Gly growth effect by PT extract is not caused just as a result of increase in survived cells, and mechanisms of PT extract of axonal growth, dendritic growth, synaptic formation and cell protection may be independent each other. Previous other reports suggest that onjisaponin-F increased ChAT mRNA level, 3) and tenuifoliside B improved scopolamine-induced memory deficit.
2) Identification of active constituents for axonal regeneration and neuronal protection will be carried out future.
Ab (25-35) is not found in the Alzheimer's disease brain. However, several reports that Ab (25-35) is an active partial fragment of Ab. This fragment also forms a b-sheet structure 19) and induces neuronal death, 19, 20) neuritic atrophy, 1, 21) synaptic loss. 1, 18, 21) Also in our previous paper, it was confirmed that effects of Ab (25-35) and Ab (1-42) on neuritic atrophy and cell death were seen similarly. 10 mM Ab(1-42) induced axonal and dendritic atrophy as well as 10 mM Ab (25-35) did. The degree of the atrophy induced by Ab (25-35) wasn't different from Ab (1-42).
10) Although it was reported that mechanisms of oxidative stress might be different in Ab (1-42) and Ab (25-35), 22) we believe that varieties and aspects of resultant damages by those two peptides are quite similar. However, effects of PT extract should be investigated in future using Ab (1-42)-induced neurodegeneration models in vitro and in vivo.
The root of PT is practically used as one of crude drugs of Kampo formulation in Japan. The greatest merit of Kampo formulation is harmonized and synergic effects brought by each crude drug combined. Since PT has activities of axonal regeneration and neuronal protection in addition to cholinergic enhancement, other crude drugs which have effects on dendritic regeneration and synaptic formation, may complement the PT effects. Such Kampo formulation may be quite ideal for anti-Alzheimer's disease. Our previous studies using cultured cortical neurons and Ab (25-35)-induced dementia model mice, indicated that ginsenoside Rb 1 , a constituent of Ginseng Radix (Japanese name : Ninjin), had axonal extension and synaptic formation activity.
1) The extract of Astragali Radix (Japanese name : Ougi) had weak activity of axonal extension and comparatively strong activity of synaptic formation and neuronal protection.
23) The Alzheimer's disease mouse model which we used is thought to be the model of comparatively early phase of Alzheimer's disease, because neuronal death is hardly seen. In previous our study using this mouse model, donepezil had no clear effects against memory impairment and neuronal degeneration. 18) These suggest that only cholinergic enhancement is insufficient to recovery of the brain function. In contrast, ginsenoside Rb 1 or the extract of Astragali Radix increased memory function in the model. Considering the character of PT clarified by the present study, Kampo formulations containing PT, Ginseng Radix and Astragali Radix are candidates for the anti-dementia medicine. For example, Ninjin-youei-to contained those three crude drugs. Although positive effect of Ninjin-youeito on scopolamine-induced memory impairment was already reported, 3) it may show a potential for anti-dementia drug also in other Alzheimer's disease models in which severe neurodegeneration are progressing.
In conclusion, we found that PT extract regenerated axons and inhibited neuronal damage in culture model of Alzheimer's disease-like neurodegeneration. By characterization of PT effects, usefulness as well as an insufficiency of PT as an anti-dementia drug was clarified.
